Quantitative evaluation of lipid layer thickness and blinking in children with allergic conjunctivitis

Boyu Yang1 · Kuiyao Wen1 · Jing Li1 · Shiyao Zhang1 · Zixin Fan1 · Xiaoling Liang1 · Lingyi Liang1

Received: 8 December 2020 / Revised: 25 March 2021 / Accepted: 11 April 2021 / Published online: 18 May 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract

Purpose To quantitatively evaluate the lipid layer thickness (LLT) and blinking in children with or without allergic conjunctivitis (AC), and to compare those between the different types of AC.

Methods For this case–control study, 81 children with symptomatic AC with an average age of 9.62 ± 2.67 years were enrolled and subdivided according to the subtypes of AC, including seasonal/perennial allergic conjunctivitis group and vernal keratoconjunctivitis (VKC)/atopic keratoconjunctivitis (AKC) group. Another 82 age-matched healthy children were enrolled as control group. All subjects underwent routine eye examination and measurements of LLT, the number of incomplete or total blinking, partial blinking rate by the LipiView interferometer over a 10-s period. Other ocular surface assessment included fluorescein tear breakup time (TBUT), lower tear meniscus height, meibomian gland loss (MGL), meibum expressibility and quality.

Results Pediatric patients with AC had significant thinner LLT, shorter TBUT, decreased total blinking but increased partial blinking rate, especially in those with VKC/AKC (all \(P<0.05\)). A significant deterioration of meibomian gland parameters was observed in AC group when compared with control subjects, demonstrated by severe upper and lower MGL, lid margin abnormalities, decreased meibum expressibility, and abnormal meibum quality, all of which were worse in the severe type of AC (all \(P<0.05\)). Thinner LLT was significantly correlated with decreased TBUT (\(\beta=3.666, P<0.001\)) and severity of upper MGL (\(\beta=-7.701, P=0.002\)).

Conclusion Decreased LLT and blinking disorders in pediatric patients with AC may contribute to lipid layer deficiency in the long run, which should be considered and appropriately diagnosed for a more precise treatment.

Key Message:

- Meibomian gland dysfunction is a major long-term complication of allergic conjunctivitis (AC). However, the quantitative changes of meibomian gland function, such as lipid layer thickness (LLT) in children with AC remains unclear.

- Children with AC had decreased LLT and increased partial blinking rate, especially in those with more severe type of AC.

- Thinner LLT was significantly correlated with decreased tear breakup time and severity of upper meibomian gland loss.

- Quantitative evaluation of LLT might be useful in the assessment of the AC related dry eye in pediatric patients.

Keywords Allergic conjunctivitis · Lipid layer thickness · Blinking · Meibomian gland

Extended author information available on the last page of the article
Introduction

Allergic conjunctivitis (AC) is a worldwide common eye disease and frequently occurs in children. TFOS DEWS II classified AC as a probable risk factor for dry eyes disease (DED) [1]. In pediatric patients with AC, the prevalence of DED ranges from 12 to 97.5% [2, 3]. A growing number of literatures reported the instability of tear film in children with AC, evidenced by a decreased tear breakup time (TBUT) [2, 4–6].

Meibomian gland dysfunction (MGD) is a major long-term complication of AC [7]. It is known that the lipid layer derives from meibomian gland secretions and plays a significant role in stabilizing the tear film. As the outermost layer of the tear film, lipid layer retards tear evaporation from the aqueous layer, lowers the surface tension at the air interface, and promotes redistribution of the tear film over the ocular surface after blinking [8]. One of the previous studies, reported by Suzuki et al., assessed the alterations of lipid layer thickness (LLT) in adult patients with seasonal allergic conjunctivitis (SAC) [9]. The researchers noted an unexpected and a significant thickened LLT in SAC patients and reported a negative correlation between the LLT and TBUT. They inferred this as the compensate for the tear film instability. However, children and severe types of AC were excluded, and LLT was qualitatively evaluated in that research.

Blinking plays an integral role in ocular surface homeostasis by promoting the meibomian gland and meibium distribution into the tear film [7]. The number of complete blinking has been reported to be significantly associated with increased TBUT while incomplete blinking was associated with decreased TBUT [10]. Besides, the forceful blinking significantly increases LLT [11], and the deficiency of LLT was associated with incomplete blinking [12, 13]. Subjects exhibiting incomplete blinking had more severe MGL, reduced tear film stability, and thus trended to develop DED [10, 13, 14]. It is generally believed that the discomfort caused by AC increases blinking particularly in pediatric patients. However, the alterations of the total or incomplete blinking and the relationship between the incomplete blinking and LLT in children with AC have not been fully elucidated.

The aim of this study was to quantitatively evaluate LLT and blinking in children with active AC and compare that with healthy children, then observe the differences of LLT and blinking between the mild and severe types of AC, and finally analyze the association between the ocular surface parameters and LLT in AC group.

Materials and methods

Subjects

This cross-sectional, case–control study followed the tenets of the Declaration of Helsinki and was approved by the Medical Ethical Committee of Zhongshan Ophthalmic Center (2019KYPJ134), Sun Yat-sen University, Guangzhou, China. All the AC subjects with an age between 6 and 18 years were recruited from cornea clinic and the age-matched healthy control subjects were recruited among outpatients who visited for regular screening for refractive error at Zhongshan Ophthalmic Center from November 2019 to August 2020. Due to the impact of COVID-19, recruiting children from both groups were stopped between January 2020 and May 2020. Informed consent was obtained from all the subjects and their parents or guardian before the start of any study-related procedures.

Patients with AC were diagnosed according to the AAO diagnostic criteria for AC 2019 [15], and further subdivided into SAC/perennial allergic conjunctivitis (PAC) group and vernal keratoconjunctivitis (VKC)/atopic keratoconjunctivitis (AKC) group to understand the alterations of LLT in the different types of AC. We excluded the children who could not cooperate with our measurement, patients who had a history of ocular trauma or surgery, other ocular surface diseases such as giant papillary conjunctivitis induced by contact lens or ocular surface implant, infective conjunctivitis, lacrimal duct obstruction disease, eyelid disorders, intraocular diseases, who had worn contact lenses, used a punctal plug and topical ocular medications include eye drops and ointments within the prior 3 months. That is, all the active AC in our study were first onset or relapsed without being medicated for this episode yet. In the control group, subjects who had ocular surface or intraocular diseases were excluded, except the mild ametropia (spherical equivalent was from +3.00D to −3.00D) or mild DED.

Clinical measures

Medical history, including the duration and medication of AC history since the first episode, incidence seasons, and systemic condition such as allergic rhinitis (AR) were collected for each patient.

After examination of the best-corrected visual acuity (BCVA), refractive error (RT-5100; NIDEK, Tokyo, Japan) and intraocular pressure (T-X-200 tonometer; Canon, Japan), other ocular surface measurements were performed sequentially as follows: (1) LLT and blinking were obtained using LipiView interferometer (TearScience, Morrisville, North Carolina, USA). Considering the compliance and tolerance of the children, the examination time was adjusted to 10 s. Only the conformance factor of > 0.8 was used. The mean LLT, the number of incomplete blinking and total blinking were recorded, then the partial blinking rate was calculated as the rate between the incomplete blinking and the total blinking. (2) The
lower tear meniscus height (TMH) was measured using keratograph 5 M (K5M; Oculus, Optikgerate, Germany) in tear meniscus mode, and the mean height of three measurements was recorded. (3) Severity of AC was evaluated using slit-lamp based on the 5–5–5 exacerbation grading scale [16]. The scale consists of three graded groups and each group contains five clinical signs: 100-point-grade group (100 points for each, including active giant papillae, gelatinous infiltrates of the limbus, exfoliative epithelial keratopathy, shield ulcer, and papillary proliferation at lower palpebral conjunctiva), 10-point-grade group (10 points for each, including blepharitis, papillary proliferation with velvety appearance, Horner-Trantas spots, edema of bulbal conjunctiva and superficial punctate keratopathy), 1-point-grade group (1 point for each, including papillae at upper palpebral conjunctiva, follicular lesion at lower palpebral conjunctiva, hyperemia of palpebral conjunctiva, hyperemia of bulbal conjunctiva and lacrimal effusion). The total point is from 0 to 555. (4) TBUT measurement was performed using fluorescein through a slit-lamp with the cobalt blue filter. The sterile fluorescein strip (Tianjin Jingming New Technological Development Co., Ltd., Tianjin, China) was wetted by a drop of physiological saline and touched to the inferior fornix. Then, the children were instructed to blink three times to ensure adequate mixing of the dye and asked to refrain from blinking during the test. The interval between the last complete blink and the appearance of the first corneal black spot was measured three times consecutively with a stopwatch and the average of three measurements was calculated [5, 17]. (5) Lid margin abnormalities, meibum expressibility, and meibum quality were checked by a standard force with the sterile cotton swab. Lid margin abnormalities were scored as 0 (absent) or 1 (present) each for the following four parameters: irregularity lid margin, vascular engorgement, plugging of meibomian gland orifices, and anterior or posterior replacement of the mucocutaneous junction. The total score is from 0 to 4 [18]. The quantity and quality of meibum were evaluated and graded on the central five glands of the upper eyelid as published [19]. Specifically, the meibum expressibility was graded as follows: 0 for all glands expressible, 1 for three to four glands expressible, 2 for one to two glands expressible, and 3 for no glands expressible. The meibum quality was graded as follows: 0 for clear fluid, 1 for cloudy fluid, 2 for cloudy particulate fluid, 3 for inspissated, like toothpaste. (6) Meibomian gland loss (MGL) of the upper and lower eyelid was graded by meibography using K5M as reported [18] to generate the meiboscore, that is, 0 for no MGL, 1 for less than one-third MGL, 2 for one-third to two-third MGL, 3 for more than two-third MGL. The examination room was maintained at the temperature of 24 to 26°C and the humidity was 40 to 50% [17, 20].

Statistical analysis

All the subjects receive examinations of both eyes and only the more severe eye was analyzed. If both eyes had the same ocular surface changes, the right eye was selected. All statistical analyses were performed with SPSS Statistical Software (version 23.0; SPSS Inc., Chicago, IL, USA). Data were presented as means ± standard deviations (SD) or n (%). The normality of variables data was assessed using the Shapiro–Wilk test. Mann–Whitney U nonparametric analysis was adopted for the continuous data and ordinal categorical variable. Categorical data such as sex and the history of AR were analyzed using the Pearson Chi-Square test. The univariate and multivariate linear regression analysis were used to evaluate the impact of clinical variables on LLT in AC group. In multivariate linear regression, only significant variables in the univariate were analyzed. P values of <0.05 were considered statistically significant.

Results

A total of 81 AC pediatric patients with a mean age of 9.62 ± 2.67 years (range 6–18 years) were included in this study. The mean duration of AC history since the first episode was 19.6 ± 23.76 months (range 0–120 months). Another 82 age-matched healthy individuals were enrolled as control group. There were 23 patients with SAC, 28 with PAC, 25 with VKC and 5 with AKC. The age of SAC/PAC group and VKC/AKC group was comparable. The male in the AC group was significantly more than that of control (81.5 vs. 43.9%, P < 0.001; Table 1), especially in the VKC/AKC group (100 vs. 70.6%, P = 0.001; Table 2). The number of children with AR in the AC group was significantly more than that of control (81.5 vs. 43.9%, P < 0.001; Table 1), especially in the VKC/AKC group (100 vs. 70.6%, P = 0.001; Table 2).

The mean BCVA in the AC group was 0.85 ± 0.17, which is worse than that of control (0.96 ± 0.12, P < 0.001; Table 1). In the two subgroups of AC, a worse BCVA could be observed in patients with VKC/AKC (0.78 ± 0.19 vs. 0.89 ± 0.14, P = 0.007), for whom had longer duration of AC and worse clinical signs (all P < 0.05, Table 2).

LLT and TBUT was decreased in AC group

LLT was thinner (48.91 ± 21.62 vs. 72.29 ± 22.68 nm, P < 0.001) and TBUT was shorter (3.73 ± 2.74 vs. 7.67 ± 3.08 s, P < 0.001) in children with AC compared with control subjects (Table 1 and Fig. 1a,b). In the two subgroups of AC, a decreased LLT was observed in the VKC/AKC group when compared with the SAC/PAC group.
There were significantly decreased number of total blinking (2.68 ± 1.92 vs. 3.80 ± 2.60, \( P = 0.004 \)) and increased partial blinking rate (63.65 ± 39.06 vs. 50.59 ± 37.86, \( P = 0.024 \)) in children with AC compared with control subjects (Table 1 and Fig. 2a,b). In the two subgroups of AC, a decreased number of total blinking (2.17 ± 1.95 vs. 2.98 ± 1.86, \( P = 0.032 \)) and an increased partial blinking rate (74.72 ± 41.67 vs. 57.14 ± 36.29%, \( P = 0.014 \)) were also observed in the VKC/AKC group compared with the SAC/PAC group (Table 2 and Fig. 2c,d). However, there was no significant difference of the number of incomplete blinking in both the groups of AC and control and between the two subgroups of AC.

**Meibomian gland parameters were worse in AC group**

As shown in Table 1, there were significantly higher meiboscore in the upper and lower lids and worse lid margin abnormalities, meibum expressibility and quality in the AC group than those of the control (all \( P < 0.001 \)). In the two subgroups of AC, the meiboscore of both upper and lower was significantly higher in pediatric patients with VKC/AKC (all \( P < 0.05 \)), especially in the upper lid. Other meibomian gland parameters as lid margin abnormalities, meibum expressibility and quality were significantly more severe in the VKC/AKC group (all \( P < 0.001 \), Table 2).

**Decreased TBUT and severity of upper MGL were significantly associated with decreased LLT in AC group**

In AC group, decreased TBUT (\( \beta = 3.666, P < 0.001 \), Fig. 3a) and severity of upper MGL (\( \beta = 7.701, P = 0.002 \)) were significantly correlated with thinner LLT on both univariate and multivariate linear regression analysis. Partial blinking rate (\( \beta = -16.079, P = 0.009 \), Fig. 4a), lid margin abnormalities (\( \beta = -4.558, P = 0.041 \)), meibum expressibility (\( \beta = -5.396, P = 0.004 \)) and meibum quality (\( \beta = -5.416, P = 0.001 \)) were significantly associated with LLT only in the univariate linear regression analysis (Table 3).

In the SAC/PAC group, TBUT (\( \beta = 3.604, P = 0.001 \), Fig. 3b), upper MGL (\( \beta = -13.258, P = 0.004 \), Meibum expressibility (\( \beta = -6.665, P = 0.031 \)) and meibum quality (\( \beta = -5.953, P = 0.030 \)) were also significantly associated
Table 2 Clinical variables and ocular surface status in SAC/PAC and VKC/AKC subgroups

| Parameters                        | SAC/PAC group (n = 51) | VKC/AKC group (n = 30) | P value |
|----------------------------------|------------------------|------------------------|---------|
| Age, y                           | 9.47 ± 2.64            | 9.87 ± 2.75            | 0.443   |
| Sex, n (%)                       |                        |                        |         |
| Female                           | 15 (29.4%)             | 0 (0.0%)               | 0.001*  |
| Male                             | 36 (70.6%)             | 30 (100%)              |         |
| Allergic rhinitis, n (%)         |                        |                        |         |
| No                               | 17 (33.3%)             | 18 (60.0%)             | 0.019*  |
| Yes                              | 34 (66.7%)             | 12 (40.0%)             |         |
| The duration of AC, month        | 13.65 ± 19.21          | 29.70 ± 27.44          | 0.001*  |
| BCVA (logMAR)                    | 0.89 ± 0.14            | 0.78 ± 0.19            | 0.007*  |
| Ocular surface parameters        |                        |                        |         |
| Lipid layer thickness, nm        | 53.45 ± 23.32          | 41.20 ± 15.93          | 0.014*  |
| Incomplete blinking, n           | 1.92 ± 1.70            | 1.93 ± 1.80            | 0.912   |
| Total blinking, n                | 2.98 ± 1.86            | 2.17 ± 1.95            | 0.032*  |
| Partial blinking rate, %         | 57.14 ± 36.29          | 74.72 ± 41.67          | 0.014*  |
| TMH, mm                          | 0.17 ± 0.09            | 0.24 ± 0.18            | 0.132   |
| TBUT, s                          | 4.00 ± 2.74            | 3.27 ± 2.72            | 0.207   |
| Upper MGL (0–3)                  | 0.63 ± 0.63            | 1.63 ± 0.81            | <0.001* |
| Lower MGL (0–3)                  | 0.45 ± 0.61            | 0.93 ± 0.79            | 0.003*  |
| Lid margin abnormalities (0–4)   | 0.45 ± 0.76            | 1.60 ± 1.16            | <0.001* |
| Meibum expressibility (0–3)      | 0.75 ± 1.06            | 1.93 ± 1.29            | <0.001* |
| Meibum quality (0–3)             | 0.71 ± 1.19            | 2.13 ± 1.36            | <0.001* |
| 5-5-5 score                      | 14.02 ± 20.36          | 139.13 ± 98.70         | <0.001* |

* Significant (P < 0.05)

AC, allergic conjunctivitis; SAC, seasonal allergic conjunctivitis; PAC, perennial allergic conjunctivitis; VKC, vernal keratoconjunctivitis; AKC, atopic keratoconjunctivitis; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; TMH, tear meniscus height; TBUT, tear breakup time; MGL, meibomian gland loss

Fig. 1 Box plots showing decreased lipid layer thickness and tear breakup time in AC group vs. control group (a–b), and in VKC/AKC group vs. SAC/PAC group (c–d)
with LLT (Table 4). However, TBUT ($\beta = 3.392, P = 0.001$, Fig. 3c) and partial blinking rate ($\beta = -15.821, P = 0.023$, Fig. 4c) were significantly correlated with LLT in the VKC/AKC group (Table 5).

**Discussion**

This study quantitatively evaluated LLT and blinking pattern in pediatric patients with AC. The results showed a thinner LLT, decreased total blinking, and increased partial blinking rate in children with AC, especially in severe type of AC. The thinner LLT was associated with decreased TBUT and severity of upper MGL.

In recent years, LLT can be quantitatively measured in a noncontact way using the interferometer by analyzing the color and brightness of the lipid layer interference images [21]. In the healthy control subjects of our study, the average LLT was similar to a previous report [17], while TBUT was shorter than the data ($10.04 \pm 1.79$ s) from children in the southwest China with a mean age of $4.76 \pm 0.86$ years [3]. The average TBUT in VKC/AKC group was close to a previous study (VKC: $4.5 \pm 1.0$ s, AKC: $3.1 \pm 1.6$ s) [22], while the value in the SAC/PAC group was shorter than the reported data ($6.54 \pm 1.48$ s) from the children with a mean age of $4.75 \pm 0.83$ years [3].

Contrary to our conclusions, Suzuki et al. reported surprising results that SAC patients with tear film instability had thicker LLT and showed negative correlation with TBUT [9]. However, our current results indicated that the LLT was significantly thinner in the SAC/PAC group compared with the control group (data not shown). These discrepancies might

![Fig. 2](image-url) Box plots showing decreased total blinking and partial blinking rate in AC group vs. control group (a–b), and in VKC/AKC group vs. SAC/PAC group (c–d)

![Fig. 3](image-url) Scatter plots showing positive association between lipid layer thickness and tear breakup time in AC group (a), SAC/PAC group (b), VKC/AKC group (c)
be explained as follows: firstly, the device and the method of the measurement are different. In their study, LLT was qualitatively measured with DR-1 interferometry, and tear film instability was linked to a higher reading of the LLT measurement by this machine. In contrast, LLT of our study was quantitatively measured by LipiView interferometer, while tear film instability was associated with decreased LLT \[23, 24\]. Secondly, patient inclusion criteria were different. Children and more severe types of AC as VKC and AKC were excluded in Suzuki’s study, and none of the eyes had giant conjunctival papillae, superficial punctuate keratitis, meibomian gland disease and less than 5 mm of tear secretion in Schirmer’s test.

Anti-allergic eye drops used for previous episodes in some patients included olopatadine hydrochloride, azelastine hydrochloride, etc. Some studies have demonstrated that preservatives in anti-allergic eye drops impair the corneal and conjunctival epithelial cells \[25–28\]. That is why we excluded patients who had used topical ocular medications within 3 months prior to enrollment. However, it remains unknown whether the anti-allergic component itself has any influence on LLT; further study should be carried out to clarify this issue. Besides, we did not exclude children accompanied by AR or were using nasal sprays because AR is quite common in children with AC. In our study, no association was observed between the history of AR and LLT.

![Fig. 4](image)

**Fig. 4** Scatter plots showing negative association between lipid layer thickness and partial blinking rate in AC group (a) and VKC/AKC group (c), but not in SAC/PAC group (b).

| Factors | Univariate regression | Multivariate regression |
|---------|----------------------|------------------------|
|         | \( \beta \) (95% CI) | \( P \) value | \( \beta \) (95% CI) | \( P \) value |
| Age     | 0.591 (−1.216 to 2.398) | 0.517 | 0.591 (−1.216 to 2.398) | 0.517 |
| Sex     | −8.042 (−20.296 to 4.211) | 0.195 | −8.042 (−20.296 to 4.211) | 0.195 |
| Allergic rhinitis | 1.206 (−8.502 to 10.914) | 0.805 | 1.206 (−8.502 to 10.914) | 0.805 |
| The duration of AC | −0.072 (−0.276 to 0.131) | 0.480 | −0.072 (−0.276 to 0.131) | 0.480 |
| BCVA    | 4.452 (−24.134 to 33.037) | 0.757 | 4.452 (−24.134 to 33.037) | 0.757 |
| Ocular surface parameters | | | | |
| Incomplete blinking | −1.396 (−4.187 to 1.396) | 0.323 | −1.396 (−4.187 to 1.396) | 0.323 |
| Total blinking | −1.330 (−3.831 to 1.170) | 0.293 | −1.330 (−3.831 to 1.170) | 0.293 |
| Partial blinking rate | −16.079 (−27.938 to −4.220) | 0.009* | −16.079 (−27.938 to −4.220) | 0.009* |
| TMH     | −21.556 (−57.820 to 14.709) | 0.240 | −21.556 (−57.820 to 14.709) | 0.240 |
| TBUT    | 4.347 (2.871 to 5.822) | <0.001* | 3.666 (2.214 to 5.118) | <0.001* |
| Upper MGL | −11.052 (−16.170 to −5.933) | <0.001* | −11.052 (−16.170 to −5.933) | <0.001* |
| Lower MGL | −2.729 (−9.473 to 4.014) | 0.423 | −2.729 (−9.473 to 4.014) | 0.423 |
| Lid margin abnormalities | −4.558 (−8.936 to −0.180) | 0.041* | −4.558 (−8.936 to −0.180) | 0.041* |
| Meibum expressibility | −5.396 (−8.993 to −1.799) | 0.004* | −5.396 (−8.993 to −1.799) | 0.004* |
| Meibum quality | −5.416 (−8.588 to −2.244) | 0.001* | −5.416 (−8.588 to −2.244) | 0.001* |
| 5-5-5 score | −0.020 (−0.075 to 0.036) | 0.488 | −0.020 (−0.075 to 0.036) | 0.488 |

* Significant (\( P < 0.05 \))

AC, allergic conjunctivitis; BCVA, best-corrected visual acuity; TMH, tear meniscus height; TBUT, tear breakup time; MGL, meibomian gland loss; CI, confidence interval.
Table 4 The univariate and multivariate linear regression analysis to evaluate the factors associated with LLT in SAC/PAC subgroup

| Factors                              | Univariate regression | Multivariate regression |
|--------------------------------------|-----------------------|-------------------------|
|                                      | $\beta$ (95% CI)      | $P$ value               | $\beta$ (95% CI)      | $P$ value               |
| Age                                  | 0.385 (−2.148 to 2.917) | 0.761                   | 0.385 (−2.148 to 2.917) | 0.761                   |
| Sex                                  | −2.856 (−17.379 to 11.668) | 0.694                   | −2.856 (−17.379 to 11.668) | 0.694                   |
| Allergic rhinitis                    | −9.382 (−23.182 to 4.417) | 0.178                   | −9.382 (−23.182 to 4.417) | 0.178                   |
| The duration of AC                   | 0.025 (−0.323 to 0.374)  | 0.884                   | 0.025 (−0.323 to 0.374)  | 0.884                   |
| BCVA                                 | 12.650 (−33.758 to 59.058) | 0.586                   | 12.650 (−33.758 to 59.058) | 0.586                   |
| Ocular surface parameters            |                       |                         |                         |                         |
| Incomplete blinking                  | −0.273 (−4.221 to 3.675) | 0.890                   | −0.273 (−4.221 to 3.675) | 0.890                   |
| Total blinking                       | −1.790 (−5.352 to 1.773) | 0.318                   | −1.790 (−5.352 to 1.773) | 0.318                   |
| Partial blinking rate                | −11.524 (−29.668 to 6.620) | 0.208                   | −11.524 (−29.668 to 6.620) | 0.208                   |
| TMH                                  | 19.523 (−58.160 to 97.206) | 0.616                   | 19.523 (−58.160 to 97.206) | 0.616                   |
| TBUT                                 | 4.556 (2.495 to 6.617)  | <0.001*                 | 3.604 (1.598 to 5.610)  | 0.001*                  |
| Upper MGL                            | −18.143 (−27.380 to −8.905) | 0.084                   | −13.258 (−21.974 to −4.543) | 0.004*                  |
| Lower MGL                            | 2.503 (−8.440 to 13.447)  | 0.648                   | 2.503 (−8.440 to 13.447)  | 0.648                   |
| Lid margin abnormalities             | −7.977 (−16.552 to 0.568) | 0.067                   | −7.977 (−16.552 to 0.568) | 0.067                   |
| Meibum expressibility                | −6.665 (−12.712 to −0.617) | 0.031*                 | −6.665 (−12.712 to −0.617) | 0.031*                 |
| Meibum quality                       | −5.953 (−11.322 to −0.585) | 0.030*                 | −5.953 (−11.322 to −0.585) | 0.030*                 |
| 5-5-5 score                          | 0.155 (−0.171 to 0.481)   | 0.344                   | 0.155 (−0.171 to 0.481)   | 0.344                   |

* Significant ($P < 0.05$)

AC, allergic conjunctivitis; BCVA, best-corrected visual acuity; TMH, tear meniscus height; TBUT, tear breakup time; MGL, meibomian gland loss; CI, confidence interval

Table 5 The univariate and multivariate linear regression analysis to evaluate the factors associated with LLT in VKC/AKC subgroup

| Factors                              | Univariate regression | Multivariate regression |
|--------------------------------------|-----------------------|-------------------------|
|                                      | $\beta$ (95% CI)      | $P$ value               | $\beta$ (95% CI)      | $P$ value               |
| Age                                  | 1.343 (−0.838 to 3.524) | 0.218                   | 1.343 (−0.838 to 3.524) | 0.218                   |
| Sex                                  | -                     | -                       | -                     | -                       |
| Allergic rhinitis                    | 9.528 (−2.289 to 21.345) | 0.110                   | 9.528 (−2.289 to 21.345) | 0.110                   |
| The duration of AC                   | −0.001 (−0.226 to 0.224) | 0.992                   | −0.001 (−0.226 to 0.224) | 0.992                   |
| BCVA                                 | −27.012 (−57.935 to 3.911) | 0.084                   | −27.012 (−57.935 to 3.911) | 0.084                   |
| Ocular surface parameters            |                       |                         |                         |                         |
| Incomplete blinking                  | −3.085 (−6.299 to 0.129) | 0.059                   | −3.085 (−6.299 to 0.129) | 0.059                   |
| Total blinking                       | −2.469 (−5.486 to 0.548) | 0.105                   | −2.469 (−5.486 to 0.548) | 0.105                   |
| Partial blinking rate                | −15.821 (−29.299 to −2.343) | 0.023*                 | −15.821 (−29.299 to −2.343) | 0.023*                 |
| TMH                                  | −22.752 (−55.839 to 10.335) | 0.170                   | −22.752 (−55.839 to 10.335) | 0.170                   |
| TBUT                                 | 3.392 (1.538 to 5.245)  | 0.001*                  | 3.392 (1.538 to 5.245)  | 0.001*                  |
| Upper MGL                            | −2.467 (−10.035 to 5.100) | 0.510                   | −2.467 (−10.035 to 5.100) | 0.510                   |
| Lower MGL                            | −2.608 (−10.402 to 5.185) | 0.499                   | −2.608 (−10.402 to 5.185) | 0.499                   |
| Lid margin abnormalities             | 1.821 (−3.437 to 7.080)  | 0.484                   | 1.821 (−3.437 to 7.080)  | 0.484                   |
| Meibum expressibility                | −1.182 (−5.962 to 3.597)  | 0.616                   | −1.182 (−5.962 to 3.597)  | 0.616                   |
| Meibum quality                       | −2.428 (−6.872 to 2.017)   | 0.273                   | −2.428 (−6.872 to 2.017)   | 0.273                   |
| 5-5-5 score                          | 0.050 (−0.010 to 0.109)   | 0.098                   | 0.050 (−0.010 to 0.109)   | 0.098                   |

* Significant ($P < 0.05$)

AC, allergic conjunctivitis; BCVA, best-corrected visual acuity; TMH, tear meniscus height; TBUT, tear breakup time; MGL, meibomian gland loss; CI, confidence interval
The potential influence of nasal condition or the use of nasal sprays on LLT was still unclear, and further comparative study might answer these questions.

Frequent eye blinking is believed common in children with AC, especially concomitant with DED. However, there was no research to confirm this. In our report on the quantitative measurement of blinking in pediatric patients with AC, the results showed a decreased total blinking in the AC group, especially in those with VKC/AKC. Whereas, there was no statistical significance of total blinking between the SAC/PAC group and control group (data not shown). The decreased total blinking in patients with VKC/AKC might relate to the mechanical insult to the cornea caused by the giant papillae or the proliferative lesion in the upper palpebral conjunctiva. Furthermore, LLT decreased and partial blinking rate increased more significantly in the severe type of AC. According to the previously reported [12, 13], we could speculate that the decreased total blinking and the increased partial blinking rate might reduce the meibum expelling and distribution into the ocular surface, thus leading to a thinner LLT.

In addition, TMH was measured to evaluate the quantity of tear secretion. Although a watery eye is a common clinical sign of AC [15], our results showed a lack of significant difference of TMH between the AC and control group, which suggested that pediatric patients with AC have relatively normal tear secretion. Consistent with TFOS DEWS II [7], more AC children in our study have evaporative dry eye rather than the aqueous tear deficiency type of dry eye.

Next, we evaluated the meibomian gland between different groups. A significantly higher upper and lower MGL and worse lid margin abnormalities, meibum expressibility and quality were discovered in pediatric patients with AC, especially in those with VKC/AKC. MGD, lid margin abnormality, and the changes of lipid composition give rise to the hyposecretion of lipids and tear film instability [29, 30]. Previous confocal microscopy examinations in patients with VKC and AKC have disclosed that the extensive periglandular inflammatory cell infiltration accelerates meibomian gland fibrosis and atrophy, decreases in size and density of the meibomian gland acinar unit, increases lid margin vascularity and hyperkeratinization, and promotes orifice obliteration and narrowing [31–33]. Moreover, a significantly more frequent upper meibomian gland duct distortion in patients with PAC due to the inflammatory changes in conjunctival tissue and the frequently rub eyes was found, leading to a poor quality and quantity meibomian expression [34]. It can be concluded that the inflammatory mediator infiltration and the repeatedly rubbed eyes in AC children may damage the structure and function of meibomian gland, and consequently cause alterations in the meibum quality or quantity, ultimately decrease LLT and aggravate tear stability.

In the multivariate linear regression analysis, the severity of upper MGL was statistically correlated with thinner LLT in the AC group. One of the possible reasons is that the papillary hypertrophy or proliferative lesion mainly occurred in the upper eyelid, and thus the long-term and recurrent inflammation stimulation is more likely to cause the upper MGL, especially in patients with VKC and AKC. In addition, the upper meibomian gland contributes more to the lipid pool and subsequently to the LLT [29]. Compared with the lower eyelid, the upper eyelid has more pronounced movements during blinking, which promotes the squeezing of upper meibomian gland. Besides, the direction of meibum secretion in the upper eyelid is consistent with the gravity direction, making the secretion more easily and continuously. Moreover, the upper meibomian glands are larger in number and have a longer length, and hence have approximately double total volume and secretory capacity versus the lower meibomian gland [29, 35].

One weakness of the present study is the small sample size, especially in the relatively rare type of AKC. The second weakness is that the ocular surface disease index questionnaire was not performed in our study because the questionnaire is unsuitable for children. Lastly, all the patients in the AC group were in the disease active stage, and the changes of LLT after anti-allergic therapy were not evaluated. Future research with a larger sample size of each group and the comparison of LLT before and after treatment are still needed.

In conclusion, children with AC had lipid tear deficiency as decreased LLT and blinking disorders. Thinner LLT was associated with decreased tear stability and severity of upper MGL. Evaluation of LLT might shed light on the plausible mechanism of DED associated with AC in pediatric patients and provide meaningful reference for a more precise treatment. Future research with a larger sample size is still needed.

Author contribution All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Boyu Yang, Kuiyao Wen, Jing Li, Shiyao Zhang, and Zixin Fan. The first draft of the manuscript was written by Boyu Yang, Xiaoling Liang, and Lingyi Liang, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding This study was supported by grants (81770892, 82070922) from the National Natural Science Foundation of China, a grant (2019A1515012012) from the Natural Science Foundation of Guangdong Province. The sponsors or funding organizations had no role in the design or conduct of this research; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Data availability Data are not transparent.
Code availability Not applicable.

Declarations

Ethics approval and consent to participate The research protocol was approved by the Medical Ethical Committee of Zhongshan Ophthalmic Center (2019KYJ134), Sun Yat-sen University, and written informed consent was obtained from each patient. The study adhered to the tenets of Declaration of Helsinki.

Consent for publication Consent was obtained from each author.

Conflict of interest The authors declare no competing interests.

References

1. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, Viso E, Vitale S, Jones L (2017) TFOS DEWS II epidemiology report. Ocul Surf 15:334–365
2. Akil H, Celik F, Ulas F, Kara IS (2015) Dry eye syndrome and allergic conjunctivitis in the pediatric population. Middle East Afr J Ophthalmol 22:467–471
3. Chen L, Pi L, Fang J, Chen X, Ke N, Liu Q (2016) High incidence of dry eye in young children with allergic conjunctivitis in Southwest China. Acta Ophthalmol 94:e727–730
4. Kim TH, Moon NJ (2013) Clinical correlations of dry eye syndrome and allergic conjunctivitis in Korean children. J Pediatr Ophthalmol Strabismus 50:124–127
5. Dogru M, Gunay M, Celik G, Aktsa A (2016) Evaluation of the tear film instability in children with allergic diseases. Cutan Ocul Toxicol 35:49–52
6. Villani E, Strologo MD, Pichi F, Luccarelli SV, De Cilla S, Serafino M, Nucci P (2015) Dry eye in vernal keratoconjunctivitis: a cross-sectional comparative study. Medicine (Baltimore) 94:e1648
7. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, Sullivan DA (2017) TFOS DEWS II pathophysiology report. Ocul Surf 15:438–510
8. Willcox MDP, Argueso P, Georgiev GA, Holopainen JM, Laurie GW, Millar TJ, Papas EB, Rolland JP, Schmidt TA, Stahl U, Suarez T, Subbaraman LN, Ucakhan OO, Jones L (2017) TFOS DEWS II tear film report. Ocul Surf 15:366–403
9. Suzuki S, Goto E, Dogru M, Asano-Kato N, Matsumoto Y, Hara Y, Fujishima H, Tsubota K (2006) Tear film lipid layer alterations of allergic conjunctivitis. Cornea 25:277–280
10. Jie Y, Sella R, Feng J, Gomez ML, Afshari NA (2019) Evaluation of incomplete blinking as a measurement of dry eye disease. Ocul Surf 17:440–446
11. Korb DR, Baron DF, Herman JP, Finnermore VM, Exford JM, Hermosa JL, Leahy CD, Glonek T, Greiner JV (1994) Tear film lipid layer thickness as a function of blinking. Cornea 13:354–359
12. Kawashima M, Tsubota K (2013) Tear lipid layer deficiency associated with incomplete blinking: a case report. BMC Ophthalmol 13:34
13. Wang MTM, Tien L, Han A, Lee JM, Kim D, Markoulli M, Craig JP (2018) Impact of blinking on ocular surface and tear film parameters. Ocul Surf 16:424–429
14. Hirota M, Uozato H, Kawamorita T, Shibata Y, Yamamoto S (2013) Effect of incomplete blinking on tear film stability. Optom Vis Sci 90:650–657
15. Varu DM, Rhee MK, Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, Lin A, Musch DC, Mah FS, Dunn SP, American Academy of Ophthalmology Preferred Practice Pattern C, External Disease P (2019) Conjunctivitis preferred practice pattern(R). Ophthalmology 126:P94–P169
16. Shoji J, Inada N, Sawa M (2009) Evaluation of novel scoring system named 5-5-5 exacerbation grading scale for allergic conjunctivitis disease. Allergol Int 58:591–597
17. Mizoguchi T, Arita R, Fukuoka S, Morishige N (2017) Morphology and function of meibomian glands and other tear film parameters in junior high school students. Cornea 36:922–926
18. Arita R, Itoh K, Inoue K, Amano S (2008) Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology 115:911–915
19. Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EL, Yee R, Yokoi N, Arita R, Dogru M (2011) The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci 52:2006–2049
20. Zhao Y, Chen S, Wang S, Chen Y, Li J, Fu Y, Dai Q, Lin X, Wu Y, Zhao Y (2018) The significance of meibomian gland changes in asymptomatic children. Ocul Surf 16:301–305
21. Eom Y, Lee JS, Kang SY, Kim HM, Song JS (2013) Correlation between quantitative measurements of tear film lipid layer thickness and meibomian gland loss in patients with obstructive meibomian gland dysfunction and normal controls. Am J Ophthalmol 155(1104–1110):e1102
22. Hu Y, Matsumoto Y, Dogru M, Okada N, Igarashi A, Fukagawa K, Tsubota K, Fujishima H (2007) The differences of tear function and ocular surface findings in patients with atopic keratoconjunctivitis and vernal keratoconjunctivitis. Allergy 62:917–925
23. Jung JW, Park SY, Kim JS, Kim EK, Seo KY, Kim T (2016) Analysis of factors associated with the tear film lipid layer thickness in normal eyes and patients with dry eye syndrome. Invest Ophthalmol Vis Sci 57:4076–4083
24. Finis D, Pischel N, Schrader S, Geerling G (2013) Evaluation of lipid layer thickness measurement of the tear film as a diagnostic tool for Meibomian gland dysfunction. Cornea 32:1549–1553
25. Kim SI, Park CY, Fordjour G, Lee JH, Lee JS, Lee JE (2019) Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents. BMC Ophthalmol 19:217
26. Pauly A, Brasnu E, Riancho L, Brignole-Baudouin F, Baudouin C (2011) Multiple endpoint analysis of BAC-preserved and unpreserved antiallergy eye drops on a 3D-reconstituted corneal epithelial model. Mol Vis 17:745–755
27. Guzman-Aranguez A, Calvo P, Ropero I, Pintor J (2014) In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells. J Ocul Pharmacol Ther 30:790–798
28. Ayaki M, Iwasawa A, Yaguchi S, Koide R (2010) Preserved and unpreserved 12 anti-allergic ophthalmic solutions and ocular surface toxicity: in vitro assessment in four cultured corneal and conjunctival epithelial cell lines. Biocontrol Sci 15:143–148
29. Knop E, Knop N, Millar T, Obata H, Sullivan DA (2011) The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci 52:1938–1978
30. Green-Church KB, Butovich I, Willcox M, Borchman D, Paulsen F, Barabino S, Glasgow BJ (2011) The international workshop on meibomian gland dysfunction: report of the subcommittee on tear film lipids and lipid-protein interactions in health and disease. Invest Ophthalmol Vis Sci 52:1979–1993
31. Le Q, Hong J, Zhu W, Sun X, Xu J (2011) In vivo laser scanning confocal microscopy of vernal keratoconjunctivitis. Clin Exp Ophthalmol 39:53–60
32. Ibrahim OM, Matsumoto Y, Dogru M, Adan ES, Wakamatsu TH, Shimazaki J, Fujishima H, Tsubota K (2012) In vivo confocal
33. Wei Q, Le Q, Hong J, Xiang J, Wei A, Xu J (2015) In vivo confocal microscopy of meibomian glands and palpebral conjunctiva in vernal keratoconjunctivitis. Indian J Ophthalmol 63:327–330

34. Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Tomidokoro A, Amano S (2010) Meibomian gland duct distortion in patients with perennial allergic conjunctivitis. Cornea 29:858–860

35. Eom Y, Choi KE, Kang SY, Lee HK, Kim HM, Song JS (2014) Comparison of meibomian gland loss and expressed meibum grade between the upper and lower eyelids in patients with obstructive meibomian gland dysfunction. Cornea 33:448–452

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Boyu Yang¹ · Kuiyao Wen¹ · Jing Li¹ · Shiyao Zhang¹ · Zixin Fan¹ · Xiaoling Liang¹ · Lingyi Liang¹

✉ Xiaoling Liang
liangxlsums@qq.com

✉ Lingyi Liang
lianglingyi@gzzoc.com

¹ State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou 510000, Guangdong, China